enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Up 10,151.1% in May

enGene Holdings Inc. (NASDAQ:ENGNW) saw a significant increase in short interest in May. As of May 15th, there was short interest totaling 40,902 shares, an increase of 10,151.1% from the April 30th total of 399 shares. Based on an average daily volume of 41,526 shares, the days-to-cover ratio is presently 1.0 days.

enGene Stock Down 0.8%

ENGNW traded down $0.00 during trading on Wednesday, reaching $0.26. 460 shares of the stock were exchanged, compared to its average volume of 18,492. The business’s 50 day moving average price is $1.72 and its two-hundred day moving average price is $2.47. enGene has a 1 year low of $0.11 and a 1 year high of $4.20.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.